Speakers

Expand/Collapse

Jessica Kirshner
Senior Director of Oncology
Regeneron Pharmaceuticals

Day One

Wednesday, June 30, 2021

6:10 pm | Chair’s Closing Remarks

Alison Crawford
Associate Director of Immuno-oncology
Regeneron

Pre-Conference Workshop

June 29, 2021

12:05 pm | Speaker Q&A

11:15 am | Examining Toxicity Mitigation Strategies To CD3 Bispecifics In Humanized Mouse Models

Marta Germani
Research Analyst
Beacon Targeted Therapies

Day One

Wednesday, June 30, 2021

8:20 am | Landscape Review of CD3 Bispecifics

9:35 am | Live Q&A - Ask our Speakers Your Burning Questions

Eric Vivier
Chief Scientific Officer
Innate Pharma

Day One

Wednesday, June 30, 2021

11:00 am | Multi-functional Natural Killer Cell Engagers

12:15 pm | Live Q&A - Ask our Speakers Your Burning Questions

Mohamed Elmeliegy
Associate Director Clinical Pharmacology
Pfizer

Pre-Conference Workshop

June 29, 2021

12:45 pm | Round Table: Developing A Dosing Strategy For Clinical Trial Investigations

Matthew Weinstock
Chief Technology Officer
Absci

Day Two

Thursday, July 1, 2021

9:30 am | Production of T Cell Engagers and complex protein therapeutics using E. coli SoluProâ

9:45 am | Live Q&A - Ask our Speakers Your Burning Questions

Erin Meermeier
Senior Research Fellow
Mayo Clinic

Pre-Conference Workshop

June 29, 2021

1:45 pm | Developing Combination Approaches Using Immunocompetent Vk*MYChCRBN Genetically Engineered Humanized Model Of Multiple Myeloma

Maya Kotturi
Director of Preclinical Biomarkers
IGM Biosciences

Pre-Conference Workshop

June 29, 2021

2:10 pm | Developing A Preclinical Biomarker Strategy For Assessing Efficacy and Safety of Bispecific T Cell Engagers

Peter Pavlik
Director of Molecular Biology and Antibody Engineering
Aptevo Therapeutics

Day One

Wednesday, June 30, 2021

10:35 am | Live Q&A - Ask our Speakers Your Burning Questions

9:45 am | Engineering of APVO442, a bispecific molecule with high affinity tumor targeting and low affinity binding to CD3 to potentially improve efficacy in solid tumors

Catherine McMahan
Senior Director of Pharmacology & Cell Sciences
Aptevo Therapeutics

Day Two

Thursday, July 1, 2021

11:30 am | Panel Discussion: Risk Mitigation Measures & Dosing Strategy for Cell Engager Drug Candidates

Hilario Ramos
Senior Director of Immuno-Biology
Aptevo Therapeutics

Day One

Wednesday, June 30, 2021

4:00 pm | APVO603: A distinct dual agonistic bispecific approach to facilitate anti-tumor activity and overcome limitations of monoclonal OX-40 and 4-1BB targeting

4:10 pm | Live Q&A - Ask our Speakers Your Burning Questions

Chris Hughes
CSO
Aracari Biosciences

Day One

Wednesday, June 30, 2021

12:45 pm | Live Q&A - Ask our Speakers Your Burning Questions

12:30 pm | The Promise of Vascularized Micro-Organs & Tumors for Drug Discovery

James Keck
Senior Director, Innovation and Product Development
The Jackson Laboratory

Suhasini Iyer
Chief Development Officer
TeneoBio

Day Two

Thursday, July 1, 2021

11:30 am | Panel Discussion: Risk Mitigation Measures & Dosing Strategy for Cell Engager Drug Candidates

Pieter Fokko van Loo
Senior Director, Oncology - Immunology
Merus

Day One

Wednesday, June 30, 2021

12:15 pm | Live Q&A - Ask our Speakers Your Burning Questions

11:25 am | Triclonics™ ENGAGE: Trispecific Antibody Platform for Tumor Specific T-Cell Engagers

Christian Klein
Department Head Cancer Immunotherapy Discovery
Roche

Day One

Wednesday, June 30, 2021

9:35 am | Live Q&A - Ask our Speakers Your Burning Questions

8:45 am | Novel Approaches for T-Cell Engagement

Bryan Irving
Chief Scientific Officer
Amunix Pharmaceuticals

Andrew Pierce
VP Translational Biology
Crescendo Biologics

Day One

Wednesday, June 30, 2021

3:20 pm | Live Q&A - Ask our Speakers Your Burning Questions

2:30 pm | CB307 Tri-Partite Humabody® Enhances T-Cells Through PSMA-Dependent CD137 (4-1BB) Agonism

Nelly Kuklin
VP Immunology
Compass Therapeutics

Day One

Wednesday, June 30, 2021

12:15 pm | Live Q&A - Ask our Speakers Your Burning Questions

11:50 am | Bispecific Anti-PD-1/PD-L1 Antibody CTX-8371 Promotes Immunological Synapse Formation & PD-1 Shedding With Superior Anti-Tumor Activity & Favorable Tolerability

Yiping Rong
Head of Discovery Biology
Harbour Biomed

Day One

Wednesday, June 30, 2021

4:10 pm | Live Q&A - Ask our Speakers Your Burning Questions

3:35 pm | HBICETM-Based B7H4x4-1BB Bispecific Provides Tumor Specific 2nd Costimulatory Signal & Anti-Tumor Immune Response

Nicholas Huntington
Co-Founder & Chief Scientific Officer
oNKo-innate

Day Two

Thursday, July 1, 2021

3:20 pm | Live Q&A - Ask our Speakers Your Burning Questions

2:05 pm | Tuning the NK Cell Response to Soluble Factors in the Tumor Microenvironment

Tatiana Novobrantseva
Co-Founder & Chief Scientific Officer
Verseau Therapeutics

Day Two

Thursday, July 1, 2021

3:20 pm | Live Q&A - Ask our Speakers Your Burning Questions

2:30 pm | Macrophage Repolarization as a Key Strategy in Changing Tumor Microenvironment

Saileta Prabhu
VP/Global Head, Clinical Biomarker Innovation & Development
Takeda

Day Two

Thursday, July 1, 2021

4:35 pm | Live Q&A - Ask our Speakers Your Burning Questions

3:45 pm | ROI on Clinical Biomarkers, CDx and Precision Medicine

David DiLillo
Associate Director
Regeneron Pharmaceuticals

Day One

Wednesday, June 30, 2021

10:35 am | Live Q&A - Ask our Speakers Your Burning Questions

10:10 am | Benchmarking T-cell -Redirecting Therapies for Cancer: Comparing Bispecifics & CAR T Cells

Patricia Giblin
VP of Biology
Revitope Oncology

Day Two

Thursday, July 1, 2021

11:30 am | Panel Discussion: Risk Mitigation Measures & Dosing Strategy for Cell Engager Drug Candidates

10:50 am | Live Q&A - Ask our Speakers Your Burning Questions

10:00 am | Improving the Therapeutic Index with Guided Antibody Tumor Engagers (GATETM)

Maria Wendt
Head of Biologics Research & Global Head Digital Biologics Platform
Sanofi

Floris van Delft
Chief Scientific Officer
Synaffix

Day Two

Thursday, July 1, 2021

9:45 am | Live Q&A - Ask our Speakers Your Burning Questions

9:05 am | Generation of Bispecific & Trispecific T-Cell & NK Cell- Engagers From Any IgG Without Prior Reengineering

Fernanda Arnaldez
Executive Director - Medical & Global Clinical Development
MacroGenics

Wim van Schooten
Chief Scientific Officer
TeneoBio

Day Two

Thursday, July 1, 2021

1:55 pm | Live Q&A - Ask our Speakers Your Burning Questions

1:30 pm | Safety & Efficacy of T-Cell Engagers with Low Agonist Activity in Oncology & Infectious Diseases

Chad May
SVP Research & Development
Maverick Therapeutics

Day One

Wednesday, June 30, 2021

1:20 pm | Panel Discussion: Mitigation Against On-Target, Off Tumor

Brian Rabinovich
Director
EMD Serono

Day One

Wednesday, June 30, 2021

1:20 pm | Panel Discussion: Mitigation Against On-Target, Off Tumor

Lukas Roth
Senior Scientist, Protein Engineering and Antibody Technologies
Merck KGaA

Day One

Wednesday, June 30, 2021

5:55 pm | Live Q&A - Ask our Speakers Your Burning Questions

4:40 pm | Affinity Maturation of B7-H6 Translates Into Enhanced NK Cell-Mediated Tumor Cell Lysis & Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement

Michael Hedvat
Associate Director
Xencor

Day One

Wednesday, June 30, 2021

3:20 pm | Live Q&A - Ask our Speakers Your Burning Questions

4:10 pm | Live Q&A - Ask our Speakers Your Burning Questions

2:55 pm | Tumor-Targeted CD28 Costimulatory Bispecific Antibodies Enhance T-Cell Activation in Solid Tumors

Joachim Koch
Head of Translational Research & Innovation
Affimed GmbH

Day One

Wednesday, June 30, 2021

5:55 pm | Live Q&A - Ask our Speakers Your Burning Questions

5:30 pm | Combination Therapies with Innate Cell Engagers to Fight for Patients in Need

Julie Bailis
Director of Research
Amgen

Day One

Wednesday, June 30, 2021

9:35 am | Live Q&A - Ask our Speakers Your Burning Questions

9:10 am | Targeting Prostate Cancer with T-Cell Engager Immune Therapies

Day Two

Thursday, July 1, 2021

11:30 am | Panel Discussion: Risk Mitigation Measures & Dosing Strategy for Cell Engager Drug Candidates

Janet Peper
Senior Scientist, Translational Science
Pieris Pharmaceuticals

Day One

Wednesday, June 30, 2021

3:20 pm | Live Q&A - Ask our Speakers Your Burning Questions

2:05 pm | 4-BB Agonism in Immuno-Oncology - Presenting Our Immunotherapy Approaches Using Tumor-Localized 4-1BB Engagement

Divya Mathur
Director of Immuno-oncology
Regeneron Pharmaceuticals

Day One

Wednesday, June 30, 2021

1:20 pm | Panel Discussion: Mitigation Against On-Target, Off Tumor

Day Two

Thursday, July 1, 2021

8:30 am | Chair’s Opening Remarks

Nuzhat Pathan
Senior Director, Translational and Immuno-Oncology
Pfizer

Day Two

Thursday, July 1, 2021

4:35 pm | Live Q&A - Ask our Speakers Your Burning Questions

4:10 pm | Biomarker strategies for optimal Immuno-Oncology combinations

Danielle Dettling
Senior Director, Pre- Clinical Pharmacology
Maverick Therapeutics

Day Two

Thursday, July 1, 2021

10:25 am | Utilizing its conditionally activated COBRA platform in the solid tumor space to demonstrate an improved therapeutic window over conventional T-cell engagers

10:50 am | Live Q&A - Ask our Speakers Your Burning Questions

Gosia Nocula-Lugowska
Principal Scientist
Pfizer

Day Two

Thursday, July 1, 2021

8:40 am | Optimizing T-cell Bispecifics in the Treatment of Solid Tumors

9:45 am | Live Q&A - Ask our Speakers Your Burning Questions

Pre-Conference Workshop

June 29, 2021

12:05 pm | Speaker Q&A

11:40 am | Review Types and Sources of Toxicity for T-Cell Retargeting Bi and Multi-Specific Antibodies

Rick Austin
Vice President, Research
Harpoon Therapeutics

Day Two

Thursday, July 1, 2021

3:20 pm | Live Q&A - Ask our Speakers Your Burning Questions

2:55 pm | Presentation Title To Be Announced

Hans van der Vliet
CSO
Lava Therapeutics

Day One

Wednesday, June 30, 2021

5:55 pm | Live Q&A - Ask our Speakers Your Burning Questions

5:05 pm | Bispecific Antibodies to Engage Vγ9Vδ2-T Cells for Cancer Immunotherapy

Bruce Keyt
Chief Scientific Officer
IGM Biosciences

Day One

Wednesday, June 30, 2021

1:20 pm | Panel Discussion: Mitigation Against On-Target, Off Tumor

Day Two

Thursday, July 1, 2021

1:55 pm | Live Q&A - Ask our Speakers Your Burning Questions

1:05 pm | Improving the Therapeutic Window of T-Cell Engagers